Tasca Therapeutics, a Boston, MA-based biotechnology company leveraging a drug discovery platform, raised $52M in Series A funding.
The round was led by Regeneron Ventures and Cure Ventures with participation from Invus Group.
The company intends to use the funds to advance its drug discovery platform, progress its lead program, CP-383, into Phase 1/2 clinical proof-of-concept studies, and to expand its drug candidate pipeline.
Led by David Fisher, M.D., Ph.D., Scientific Co-founder, Milenko Cicmil, Ph.D., Co-founder and CEO, Xu Wu, Ph.D., Co-founder and Director, Tasca is a biotechnology company focused on discovering and developing small molecule inhibitors of auto-palmitoylated target proteins important in cancer. Its lead program, CP-383, is a first-in-class drug candidate, with preclinical activity against multiple cancer types.
